Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Mapracorat (BAY86-5319)
ZK 245186 · 2 trials · 1 indication
Eczema area and severity index
Ezcema area and severity index
| Arm | Type | Description |
|---|---|---|
| 0.01% ointment | ACTIVE_COMPARATOR | Lowest concentration |
| 0.03% ointment | ACTIVE_COMPARATOR | Middle concentration |
| 0.1% ointment | ACTIVE_COMPARATOR | Highest concentration |
| Placebo (vehicle without active) | PLACEBO_COMPARATOR | No active ingredient |
| Zk 245186 0.01% ointment | ACTIVE_COMPARATOR | Active treatment, lowest dose |
| ZK 245186 0.03% ointment | ACTIVE_COMPARATOR | Active comparator middle dose |
| ZK 245186 0.1% ointment | ACTIVE_COMPARATOR | Active comparator highest dose |
| Vehicle ointment | PLACEBO_COMPARATOR | Placebo comparator |
| Name | Type | Description |
|---|---|---|
| ZK245186 | DRUG | Daily topical application |
| Placebo (vehicle without active ingredient) | DRUG | Daily topical application |
| ZK 245186 | DRUG | Once daily topical non-occlusive application for up to 4 weeks |
| Placebo (vehicle ointment) | DRUG | Once daily topical non-occlusive application for up to 4 weeks |
Inclusion Criteria: * Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria * Body surface area affected by atopic dermatitis at or less than 15% at start of treatment Exclusion Criteria: * Pregnancy and breast-feeding * Conditions that may pose a threat to the patient or effect ...
Top 20 of 26 competitors
ZK 245186 is an investigational small molecule being studied for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It has been evaluated in Phase 2 clinical trials in adults with atopic dermatitis. It is not approved for any indication and remains in clinical development.
ZK 245186 is being developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer sponsored the clinical research conducted to date on this compound in atopic dermatitis.
ZK 245186 is in Phase 2 development. Two Phase 2 trials in atopic dermatitis have been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for any use.
ZK 245186 has been studied in two completed Phase 2 trials in atopic dermatitis: NCT01228513, which enrolled 263 patients across the United States and Japan, and NCT00944632, a dose escalation study that enrolled 64 patients in South Africa. Both were randomized, double-blind, and placebo-controlled, with total enrollment of 327 adults.
Yes, ZK 245186 and ZK245186 refer to the same investigational compound. The spelling without a space appears in the title of the dose escalation trial NCT00944632, while the spaced form is used in NCT01228513. Both names identify the same Bayer small molecule developed for atopic dermatitis.